The UK and US have reached a important bilateral deal that will maintain no levies on UK drug products entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This move ensures that import taxes on these vital products will stay at zero for a period of the next three years.
This agreement is in response to previous threats to significantly raise import taxes on branded pharmaceutical imports, with figures floated up to double the cost.
"This deal between the United Kingdom bolsters the global environment for innovative medicines and introduces long-overdue equity to American-British medicine commerce," an announcement said.
Trade Impact
Pharmaceuticals constitute one of the UK's biggest goods shipped to the US, which is by far the primary destination for leading British pharmaceutical firms.
Trade data show that in the 12 months prior to the third quarter, the UK sold drugs worth billions to the US. This amount accounted for nearly one-fifth of all goods exports in that span.
"This guarantee secures employment, increases investment and facilitates the UK to become a worldwide center for life sciences," a minister commented.
Specific UK Commitments
The agreement entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Last year, rebates were more than twenty percent.
Industry Background
The pact comes amid a ongoing dispute between the sector and the ministers over drug pricing and NHS adoption.
This friction were intensified by assertions that American customers were paying a premium for the identical medicines than consumers in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
